CG9081

Dénomination commerciale

non renseigné

06974323019633

B-06974323019633

Numéro de référence/catalogue

CG9081

GS1

IVDD — Général

Législation applicable

IVDD [Directive 98/79/CE relative aux dispositifs médicaux de diagnostic in vitro]

Statut

Sur le marché

Quantité

1

Description complémentaire du produit

The SARS-CoV-2 Neutralization Antibody Rapid Test Cassette is used to qualitatively detect the SARS-CoV-2 neutralization antibodies in human serum, plasma and whole blood (capillary or venous) samples. The SARS-CoV-2 is a linear single-stranded positive-stranded RNA virus that can cause a new type of coronavirus pneumonia (COVID-19) and spreads widely among people. SARS-CoV-2 virus structural proteins, including spike protein (S), envelope protein (E), membrane protein (M) and nucleocapsid protein (N). Spike protein (S) contains the receptor binding domain (RBD), which is responsible for recognizing and interacting with angiotensin converting enzyme 2 (ACE2) on the cell surface, thereby causing endocytosis into the deep lungs of the human body. The SARS-CoV-2 neutralization antibody can block the interaction between the RBD protein and ACE2, thereby protecting the people from SARS-CoV-2. This kit can be used to evaluate the immune effect after vaccination or whether neutralization antibodies were produced in the human body after infection with SARS-CoV-2. This kit is only used as an auxiliary diagnosis, not as a basis for clinical diagnosis.

URL des informations complémentaires

Aucune URL d'informations complémentaires renseignée par le fabricant.

Dimensions cliniques

Aucune dimension clinique enregistrée pour ce dispositif.

Nomenclature européenne des dispositifs médicaux — la classification produit UE attribuée à ce dispositif.

• W0105041199OTHER CORONAVIRUS REAGENTS